Phase I trial to determine the feasibility of Tc-99m-tilmanocept to image high risk plaque by SPECT/CT in patients with and without aortic and high risk coronary atherosclerotic plaques and with and without HIV infection

Trial Profile

Phase I trial to determine the feasibility of Tc-99m-tilmanocept to image high risk plaque by SPECT/CT in patients with and without aortic and high risk coronary atherosclerotic plaques and with and without HIV infection

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Atherosclerosis
  • Focus Diagnostic use; First in man
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 29 Mar 2017 Results in HIV infected subjects published in the Journal of Infectious Diseases, according to a Navidea Biopharmaceuticals media release.
    • 16 Feb 2017 Results (n=9, men) assessing aortic 99mTc-tilmanocept uptake on SPECT/CT among HIV-infected subjects with subclinical atherosclerosis versus non-HIV-infected subjects with similar Framingham Risk Scores, presented at the 24th Conference on Retroviruses and Opportunistic Infections.
    • 17 May 2016 According to a Navidea Biopharmaceuticals media release, the company will present preliminary data from this study in medical journals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top